← Back to Search

Anti-VEGF

Pan Retinal Photocoagulation for Diabetic Retinopathy

Phase 4
Waitlist Available
Led By Victor H. Gonzalez, MD
Research Sponsored by Valley Retina Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 54 weeks
Awards & highlights

Study Summary

Intravitreal injections of pegaptanib will induce the regression of Proliferative Diabetic Retinopathy (PDR) and reduce the need for retinal photocoagulation.

Eligible Conditions
  • Diabetic Retinopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~54 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 54 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Establish efficacy of intravitreal pegaptanib sodium injections in causing regression of high risk proliferative diabetic retinopathy as compared to panretinal photocoagulation
Secondary outcome measures
Establish the efficacy of intravitreal pegaptanib injections in preventing the loss of best corrected visual acuity

Trial Design

3Treatment groups
Experimental Treatment
Group I: Pan Retinal PhotocoagulationExperimental Treatment1 Intervention
Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
Group II: IV Macugen Q6Experimental Treatment1 Intervention
Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
Group III: IV Mac Q6 ArmExperimental Treatment1 Intervention
Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections

Find a Location

Who is running the clinical trial?

Valley Retina InstituteLead Sponsor
4 Previous Clinical Trials
169 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
30 Patients Enrolled for Diabetic Retinopathy
PfizerIndustry Sponsor
4,571 Previous Clinical Trials
10,923,259 Total Patients Enrolled
5 Trials studying Diabetic Retinopathy
1,471 Patients Enrolled for Diabetic Retinopathy
Victor H. Gonzalez, MDPrincipal InvestigatorValley Retina Insitute
1 Previous Clinical Trials
185 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Victor H. Gonzalez, MD 2007. "Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01486771.
All > Diabetic Retinopathy
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top